Hoth Therapeutics, a biopharmaceutical company, has completed Phase I of its In-Life dose escalation study intended for treating Eczema, it was reported yesterday.
An independent third party conducted the clinical study by monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs.
The study had two phases with the first phase of the study being completed in September of 2019.
Robb Knie, chief executive officer of Hoth Therapeutics, said, 'Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase. We believe this therapeutic candidate has the potential to provide significant benefits to people afflicted by Atopic Dermatitis. Going forward, we are focused on expanding our clinical efforts into later stage trials.'
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART